I-23 Elin Svensson Meta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials Wednesday 10:10-11:40 |
I-24 Robin Svensson The value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin Wednesday 10:10-11:40 |
I-25 Elisa Tacconi Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum Wednesday 10:10-11:40 |
I-32 Pauline Themans Prediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach Wednesday 10:10-11:40 |
I-33 Tjokosela Tikiso TB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children Wednesday 10:10-11:40 |
I-38 Iñaki F. Trocóniz An immune quantitative framework for Hepatitis B viral infection Wednesday 10:10-11:40 |
I-40 Sami Ullah Population pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients - a cerebral microdialysis study Wednesday 10:10-11:40 |
I-62 Liviawati Wu Population Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy Volunteers Wednesday 10:10-11:40 |
I-67 Jinqiu Yin Optimizing treatment of cephalosporin-resistant pneumococcal meningitis Wednesday 10:10-11:40 |
I-75 Chenyan Zhao Quantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae Wednesday 10:10-11:40 |
I-77 Yi Zheng Effect of pregnancy on raltegravir free concentrations Wednesday 10:10-11:40 |
II-12 Jose Francis AADAC gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis Wednesday 15:50-17:20 |
II-19 Silke Gastine Nonparametric Pharmacokinetic-Pharmacodynamic Modelling of Posaconazole Wednesday 15:50-17:20 |
II-20 Florence Gattacceca Pharmacokinetic-Pharmacodynamic (PKPD) model of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine Wednesday 15:50-17:20 |
II-21 Wei Gao Viral Dynamics Model Predicts Clinical Efficacy in Hepatitis C Virus (HCV) Infected Patients Using Viral Kinetic Data from Phase 1 Studies Wednesday 15:50-17:20 |
II-29 Nele Goeyvaerts Population Pharmacokinetic/Pharmacodynamic of a Toll-Like-Receptor 7 (TLR7) Agonist that Induces IP-10 and ISG15 in Cynomolgus Monkeys Wednesday 15:50-17:20 |
II-30 Antonio Goncalves Modelling hepatitis B kinetics in mice treated by a novel TLR-7 agonist, alone or in combination with entecavir Wednesday 15:50-17:20 |
II-67 Iasonas Kapralos Population Pharmacokinetics of Anidulafungin in ICU patients Wednesday 15:50-17:20 |
II-70 Yun Kim A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects and patients Wednesday 15:50-17:20 |
II-73 Anne Kümmel Building predictive longitudinal PKPD models of antimalarial combinations with Phase 2b data Wednesday 15:50-17:20 |
II-74 Franziska Isabelle Kluwe Joint model for the characterisation of cefuroxime pharmacokinetics in synovial fluid, interstitial fluid of muscle tissue and plasma Wednesday 15:50-17:20 |
III-09 Linda Aulin Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis Thursday 09:55-11:30 |
III-16 Catalina Barceló Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy Thursday 09:55-11:30 |
III-24 Robert Bies Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue Thursday 09:55-11:30 |
III-25 Henrik Bjugård Nyberg A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis. Thursday 09:55-11:30 |
III-30 Philippine Eloy Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique Thursday 09:55-11:30 |
III-50 Maxwell Chirehwa Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques Thursday 09:55-11:30 |
III-52 Young-Kyung Choi Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis Thursday 09:55-11:30 |
III-55 Perrine Courlet Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort Thursday 09:55-11:30 |
III-71 Aris Dokoumetzidis Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis Thursday 09:55-11:30 |
IV-32 Claudio Monteiro Sousa An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a. Thursday 15:10-16:40 |
IV-42 Chika Ogami Population pharmacokinetics of unbound daptomycin in hospital patients with Gram-positive infections Thursday 15:10-16:40 |
IV-47 Taniya Paiboonvong Population Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia Thursday 15:10-16:40 |
IV-49 Semra Palic Exploring dose-dependent pharmacokinetics of miltefosine in pediatric visceral leishmaniasis patients from East Africa Thursday 15:10-16:40 |
IV-52 Navarat Panjasawatwong Population pharmacokinetics of rifampicin in Vietnamese Children with Tuberculous Meningitis Thursday 15:10-16:40 |
IV-58 Philippe Pierrillas PKPD modelling of EYP001a (a novel FXR agonist) in healthy volunteers and Hepatitis B patients Thursday 15:10-16:40 |
IV-62 Teun Post An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions Thursday 15:10-16:40 |
IV-75 Stein Schalkwijk Exploring Standard and Alternative Darunavir/Ritonavir Dosing Regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modeling Thursday 15:10-16:40 |